# Ascent Biomedical Ventures

Ascent Biomedical Ventures is a Venture Capital based in New York, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** New York, NY, United States
- **Founded:** 2004
- **Assets under management:** Undisclosed
- **Website:** ascentbiomedical.com
- **LinkedIn:** https://www.linkedin.com/company/ascent-biomedical-ventures

## Regulatory record

- **Reports private funds:** No

## About

Ascent Biomedical Ventures is a venture capital firm investing in seed and early-stage biomedical technology companies. It has made 58 investments, including a Series D investment in Retrotope on August 28, 2020. The firm has 14 portfolio exits, with Orchestra BioMed exiting on January 26, 2023.

## Sectors

- Digital Health
- Healthcare Services

## Questions

### What stage does Ascent Biomedical Ventures typically target?

The firm concentrated on early-stage biomedical investments, predominantly seed and Series A rounds, with reserved capital for follow-on financing through key regulatory milestones such as FDA clearance. Its model assumed active involvement during the highest-risk translational period when clinical validation and regulatory strategy dictate outcome.

### How does the firm source its investment opportunities?

Ascent's sourcing relied on networks within academic medical centers, research hospitals, and clinician-inventor communities — channels that generalist venture funds historically underserve. This specialist origination model positioned the firm to evaluate technologies before they reached broader institutional auction processes.

### Which sectors does the firm avoid?

The firm did not pursue non-healthcare technology, consumer internet, or financial services investments. Its exclusion of horizontal software and platform businesses underscored a deliberate conviction that biomedical venture requires domain-specific operational expertise rather than generalist pattern-recognition.

### What is the firm's known posture on co-investments?

Ascent routinely syndicated deals with other specialist life-science venture investors, co-leading rounds and sharing board seats rather than pursuing control positions exclusively. This collaborative syndication model is standard practice among dedicated healthcare venture firms seeking diversified clinical-risk exposure.

## Related profiles

- [Ascend Venture Group](https://altss.com/profile/ascend-venture-group)
- [Ashcroft Sullivan & Jha](https://altss.com/profile/ashcroft-sullivan-and-jha)

---

Updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/ascent-biomedical-ventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology